Please assess the completion status of the following clinical trial:

Trial Title: Rifabutin-containing Triple Therapy for Treatment of Helicobacter Pylori

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ability and willingness to participate in the study and to sign and give informed consent~* Confirmed H. pylori infection and with previous treatment experience~Exclusion Criteria:~* Less than 18 years old~* With previous gastric surgery~* Previous history of tuberculosis~* Major systemic diseases~* Pregnancy or lactation~* Allergy to any of the study drugs Administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tetracycline Bismuth Quadruple Therapy (Type: ACTIVE_COMPARATOR): Esomeprazole 20mg bid, Bismuth Potassium Citrate 300mg bid, Tetracycline 500mg qid, Metronidazole 400mg qid
- rifabutin triple therapy (Type: EXPERIMENTAL): Esomeprazole 20mg bid, amoxicillin 1000mg bid, rifabutin 150mg bid

Based on this trial design, predict the completion outcome and termination type (if applicable).